bit.bio
bit.bio is seeking a Contracts & IP Licensing Specialist to support drafting, reviewing, and negotiating agreements related to intellectual property licensing, transfer, and commercialization. The role involves working cross-functionally to enable research collaborations and commercial opportunities, managing license portfolios, and maintaining stakeholder relationships.
Headquarters
Babraham, England, United Kingdom
Company Size
51-200 employees
Founded
2016
bit.bio is a synthetic biology company that uses its proprietary opti-ox™ technology to precisely, consistently and efficiently reprogram pluripotent stem cells into defined human cell types at scale. They supply off‑the‑shelf and bespoke iPSC‑derived cell products and services to support research, drug discovery, disease modelling and therapeutic development. bit.bio partners with pharma and biotech to accelerate target validation and cell therapy programs by delivering reproducible, well‑characterized human cells. Their platform emphasizes scalability and genetic control to replace variable primary cells and improve preclinical translational relevance.
bit.bio closes a $50 million series C round after its 2025 restructuring
Jan 12, 2026
M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio
Jan 9, 2026
bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform
Jan 10, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for bit.bio.
bit.bio expands on back of lower prices and broader distribution model
3 weeks ago